Brief: PeptiDream announces drug discovery and development agreement with Santen Pharmaceutical
Sept 25(Reuters) - PeptiDream Inc 4587.T
* Says it has entered into a broad-based multi-target
discovery
and development agreement with Santen Pharmaceutical Co Ltd
4536.T
Source text in Japanese:https://goo.gl/eyJ1eY
Further company coverage: 4587.T 4536.T
(Beijing Headline News)
((Beijing.HeadlineNews@thomsonreuters.com; +86 10 62674724;
Reuters Messaging: huafang.zhang.reuters.com@reuters.net))
Recent news on PeptiDream
See all newsTable: Peptidream 6-MTH group results (IFRS)
Brief: Peptidream Inc. - Initiation Of Phase 1 Clinical Trial By Novartis Marks Milestone For Peptidream
Brief: PeptiDream Announces First Dosing Of 64cu-Pd-29,875 In Gastric Cancer Patients
Table: Peptidream -Q1 group results (IFRS)
Brief: Peptidream Announces The Initiation Of Phase 1 Clinical Trial By Its Collaboration Partner